Benzinga.com7d
Vertex Pharmaceuticals Unusual Options Activity
Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals VRTX revealed 10 unusual trades. Delving into the ...
Business Insider2d
Vertex Pharmaceuticals (VRTX) Gets a Buy from J.P. Morgan
In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $501.00. The company’s shares ...
Nasdaq7d
Vertex Pharmaceuticals Unusual Options Activity
Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals (NASDAQ:VRTX) revealed 10 unusual trades. Delving into ...
Business Insider10d
Optimistic Outlook for Vertex Pharmaceuticals: Strong Performance, New Approvals, and Promising Pipeline Drive Buy Rating
Analyst Michael Yee of Jefferies maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of $550.00. Michael Yee’s rating is based on Vertex ...
Yahoo Finance7d
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
Vertex Pharmaceuticals (VRTX) ended the recent trading session at $470.37, demonstrating a +1.88% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...
Investopedia10d
Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval
JOSEPH PREZIOSO / AFP via Getty Images Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration. The drugmaker said the twice-daily pill, Journavx ...
The Motley Fool8d
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?
The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...
Business Insider7d
Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare sector as a whole. This time last year, the biotech ...
Business Insider10d
Vertex Pharmaceuticals (VRTX) Initiated with a Buy at Cantor Fitzgerald
Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer yesterday. The company’s shares closed yesterday ...
ETF Daily News26d
Vertex Pharmaceuticals’ (VRTX) “Outperform” Rating Reaffirmed at William Blair
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at William Blair in a research report issued on Monday,RTT News reports.
Business Insider28d
Vertex Pharmaceuticals: Strong Future Potential with Key Drug Launches and Underappreciated Opportunities
Jefferies analyst Michael Yee has maintained their bullish ... of factors that indicate strong future potential for Vertex Pharmaceuticals. The company has witnessed a significant pullback in ...